During the corresponding time, Clearpoint Neuro Inc recorded a revenue increase by 42.93 % year on year, sequentially revenue grew by 16.5 %. While revenue at the Clearpoint Neuro Inc 's corporate clients
Clearpoint Neuro Inc's Comment on Sales, Marketing and Customers
The Company provides services aimed at improving outcome predictability and optimizing preclinical and clinical workflows. Its expertise encompasses benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and the translation from preclinical to clinical settings to improve drug delivery accuracy and precision. The Company holds exclusive global commercialization rights for the ClearPoint Prism Neuro Laser Therapy System, which was cleared in September 2022 through its Swedish partner CLS. In 2025, the Company expanded into neurocritical care by acquiring IRRAS, a commercial-stage medical technology company specializing in treatments for intracerebral hemorrhage, intraventricular hemorrhage, and intracranial fluid management. The Company operates foreign wholly owned subsidiaries primarily to employ clinical services representatives serving customers in the United Kingdom and the European Union.
Rapid Advances in Neurosurgical Technology Drive Revenue Growth for ClearPoint Neuro Inc. ClearPoint Neuro, a leading provider of innovative medical devices for neurological procedures, recently announced the full market release of two groundbreaking technologies - the SmartFrame OR and the Prism Laser Therapy System. These products, designed to enhance precision and improve patient outcomes, will be showcased at the upcoming Association for Stereotactic and Functional Neurosurgery (ASSFN) conference in Nashville from June 1 - 4.The ClearPoint SmartFrame OR is an advanced surgical navigation system that combines real-time imaging with precise robotic guidance. This technology allows neurosurgeons to accurate...
Topical Therapy Shows Promising Results in Preclinical Skin Cancer Trial: A Potential Breakthrough in Preventing and Treating Skin CancersThe incidence of precancerous skin conditions and skin cancers is on the rise globally, necessitating effective preventive and treatment measures. Actinic keratosis (AK) is the most common form of precancer, affecting over 40 million Americans annually. Conventional treatment options like chemotherapy creams and photodynamic therapy, while effective, are associated with significant side effects and prolonged recovery periods. In light of these challenges, Derm-Biome Pharmaceuticals has conducted a preclinical trial to evaluate the efficacy of a topical therapy for AK and s...
Clearpoint Neuro Inc’s Comment on Sales, Marketing and Customers
The Company provides services aimed at improving outcome predictability and optimizing preclinical and clinical workflows. Its expertise encompasses benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and the translation from preclinical to clinical settings to improve drug delivery accuracy and precision. The Company holds exclusive global commercialization rights for the ClearPoint Prism Neuro Laser Therapy System, which was cleared in September 2022 through its Swedish partner CLS. In 2025, the Company expanded into neurocritical care by acquiring IRRAS, a commercial-stage medical technology company specializing in treatments for intracerebral hemorrhage, intraventricular hemorrhage, and intracranial fluid management. The Company operates foreign wholly owned subsidiaries primarily to employ clinical services representatives serving customers in the United Kingdom and the European Union.
Sources:
Clearpoint Neuro Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Clearpoint Neuro Inc’s corporate clients.
For your research, we’ve provided 9 tables on Clearpoint Neuro Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
148.69 %